Global Myofascial Treatment With Shockwave for Non-Specific Low Back Pain
CompletedNot applicableNCT07692347
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study aims to examine the effects of shockwave therapy on myofascial tissue (muscles, fascia, and connective tissue), focusing on pain reduction and improvement of mobility. The results will be compared with those of conventional manual physiotherapy. Myofascial tissue can be a source of back pain, as it may contain painful spots known as myofascial trigger points (MTrPs). Shockwave therapy can stimulate these trigger points, potentially leading to muscle and fascia relaxation and, as a result, a decrease in pain. The study investigates how focused shockwave trigger point therapy influences back function and pain perception compared to traditional physiotherapeutic treatment. Participation is voluntary. The examinations will only be carried out if you provide written informed consent. You may refuse participation or withdraw your consent at any time without any disadvantages.
Study details
- Official title
- Global Myofascial Treatment With Focused Shockwave for Non-Specific Low Back Pain: a Randomized Control Trial.
- Conditions
- Interventions
- Device: Shockwave therapy
- Procedure: Conventional physiotherapy
- Sponsor
- University Hospital Muenster
- Start date
- 2022-08-01
- Primary completion
- 2022-12-31
- Sex
- All
- Age range
- from 18 Years to 70 Years
- Results posted
- No results posted in this snapshot
- Countries
- Germany
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Chronic low back pain (LBP) of the lumbar spine lasting more than 12 weeks * age between 18 and 70 years * pain stage 1 or 2 according to Gerbershagen * female, male or diverse * capable of giving informed consent Exclusion Criteria: * Severe neurological * vascular * neoplastic or bony disorders, as well as cognitive impairments * according to the judgment and assessment of the examiner * flexisting radicular symptoms (e.g., foot drop).
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07692347